Posted by Michael Wonder on 16 Dec 2025
Palvella Therapeutics granted FDA fast track designation for Qtorin 3.9% rapamycin anhydrous gel for the treatment of angiokeratomas
16 December 2025 - Angiokeratomas are characterised by lymphatic-derived skin lesions that can persistently bleed and significantly impact quality of life; no FDA approved therapies exist for the estimated more than 50,000 diagnosed US patients
Palvella Therapeutics today announced that the FDA has granted fast track designation to Qtorin rapamycin for the treatment of angiokeratomas.
